Diabetes Drug Market Report 2025 (Global Edition)

Global Diabetes Drug Market Report 2025 Market Size Split by Drug Class (Insulin, DPP- 4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), by Diabetes Type (Type 1, Type 2), by Route of Administ...

Diabetes Drug Market Report Description

We have various report editions of Diabetes Drug Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Diabetes Drug Market Insights Video

Competitive Landscape of the Diabetes Drugs Market

In December 2022, In India, Glenmark Pharmaceuticals Ltd. launched Zita-PioMet, a novel medication for the treatment of type 2 diabetes. Teneligliptin was the first triple fixed-dose combination (FDC) introduced by the business, together with Pioglitazone and Metformin.

 (Source: https://www.financialexpress.com/healthcare/pharma-healthcare/glenmark-becomes-first-company-to-launch-triple-fixed-dose-combination-for-type-2-diabetes-in-india/2921530/)

Top Companies Market Share in Diabetes Drug Industry: (In no particular order of Rank)

• Novo Nordisk A/s
• Sanofi
• Merck & Co Inc
• Eli Lilly and Company
• AstraZeneca
• Takeda Pharmaceuticals Company Limited
• Boehringer Ingelheim International GmbH
• Novartis AG
• Johnson & Johnson Services Inc.
• Bayers AG
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of Diabetes Drugs

Which Region will dominate the Diabetes Drugs Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2023, with the United States accounting for the highest proportion of the North American diabetes medications market. According to the American Diabetes Association, over 1.4 million Americans are diagnosed with diabetes each year. Diabetes is a prominent cause of death in Canada and across North America. Because of the disease's rising prevalence, frequency, and progressive nature, new medications are being developed to provide diabetic patients with alternative treatment options.

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific market growth may be ascribed to the region's rising diabetes prevalence, and the increasing demand for diabetes treatment as a result of the high disease burden is predicted to be the key factor driving the region's growth at the highest CAGR during the forecast period.

The current report Scope analyzes Diabetes Drug Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

Diabetes Drug Market Analysis

Drug Class Segment Analysis of Diabetes Drug Market

This report categorizes competitors in the pharmaceutical and healthcare market based on their product offerings and business models. It includes key details such as definitions, benefits, applications, technological advancements, and regional advantages for each type of pharmaceutical product, including small molecule drugs, biologics, and biosimilars.

Market growth figures, such as market share percentages, revenue, and growth rates (e.g., CAGR), are provided for each segment over the specified period (2019-2023). The report covers various segments

Drug Class of Diabetes Drug analyzed in this report are as follows:

• Insulin
• DPP- 4 Inhibitors
• GLP-1 Receptor Agonists
• SGLT2 Inhibitors

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Diabetes Drug Industry. Request a Free Sample PDF!

Diabetes Type Segment Analysis of Diabetes Drug Market

This report analyzes revenue growth in the pharma and healthcare industry at global, regional, and national levels, highlighting trends and opportunities for each application. It explores how sectors like pharmaceuticals, therapy, and healthcare monitoring use innovations to address healthcare needs. Key factors include market size, revenue contributions, technological advancements (e.g., AI-driven diagnostics), and regulatory considerations. The report also covers the value chain, identifying key players and processes within the industry. For more information, please request a sample or contact our research team.

Some of the key Diabetes Type of Diabetes Drug are:

• Type 1
• Type 2

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Diabetes Drug Route of Administration Segment Analysis

According to Cognitive Market Research, the oral anti-diabetic drugs segment had the biggest market share in 2023 and is predicted to lead the North American diabetes drugs market with around USD 20 billion in revenue. Oral anti-diabetic medications are now widely accessible worldwide and are suggested for usage when type 2 diabetes therapy needs to be escalated in addition to lifestyle changes. Patients demand effective diabetic treatment choices that are minimally invasive. The FDA welcomes the development of novel pharmaceutical alternatives that can help patients better manage their disease. The FDA's Metabolism and Endocrinology Products Division is part of the Center for Drug Evaluation and Research

• Oral
• Subcutaneous
• Intravenous

Diabetes Drug Distribution Channel Segment Analysis

• Online pharmacies
• Hospital Pharmacies
• Retail pharmacies

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion